The U.S. Federal Trade Commission (FTC) challenge to Illumina’s planned $1.2 billion acquisition of Pacific Biosciences (PacBio) on anti-competitiveness grounds is unlikely to weaken its standing as the dominant company in next-generation sequencing, three analysts have concluded . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge